Arcus Biosciences (RCUS) Short-term Investments (2017 - 2026)

Arcus Biosciences' Short-term Investments history runs 10 years deep, the most recent figure standing at $621.0 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 22.86% year-over-year to $621.0 million in Q1 2026; TTM through Mar 2026 was $621.0 million, a 22.86% decrease from a year earlier, with the FY2025 full-year figure at $759.0 million, down 8.33% from the prior year.
• Short-term Investments fell to $621.0 million in Q1 2026 per RCUS's latest filing, from $759.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $900.1 million in Q2 2022 and bottomed at $593.0 million in Q3 2025.
• The 5-year median for Short-term Investments is $759.0 million (2025), against an average of $743.6 million.
• Across the five-year window, Short-term Investments surged 140.76% in 2022 and sank 33.22% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $803.0 million in 2022, then decreased by 21.3% to $632.0 million in 2023, then soared by 31.01% to $828.0 million in 2024, then retreated by 8.33% to $759.0 million in 2025, then declined by 18.18% to $621.0 million in 2026.
• Per Business Quant, the three latest RCUS Short-term Investments figures stand at $621.0 million (Q1 2026), $759.0 million (Q4 2025), and $593.0 million (Q3 2025).